Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), filed a Form 4 on August 31, 2026, disclosing the exercise of stock options and the sale of common stock on August 27, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Banerjee exercised 5,306 employee stock options at an exercise price of $1.92 per share on August 27, 2026.
  • Shares sold: 8,222 shares of common stock were disposed of on August 27, 2026, at a weighted average price of $12.0087, with individual sale prices ranging between $12.00 and $12.05, inclusive.
  • Remaining ownership: Following the transactions, Banerjee directly held 142,047 shares of common stock and 74,265 derivative securities (employee stock options).
  • 10b5-1 plan: Both transactions occurred pursuant to a Rule 10b5-1 plan adopted by Banerjee on May 14, 2026.
  • Vesting schedule: According to the filing, 25% of the shares initially subject to the option vested on April 8, 2026, with the balance vesting at a rate of 1/36th per month over the following 36 months.

Banerjee's Option Exercise and Stock Sale at Artiva Biotherapeutics

According to the Form 4 filing, Subhashis Banerjee, serving as Chief Medical Officer of Artiva Biotherapeutics, Inc., reported two transactions in the company's common stock on August 27, 2026. In the first transaction, Banerjee acquired 5,306 shares through the exercise of employee stock options carrying an exercise price of $1.92 per share, bringing his directly held common stock position to 150,269 shares following that exercise.

In the second transaction, Banerjee disposed of 8,222 shares at a weighted average sale price of $12.0087. The filing notes that sale prices ranged between $12.00 and $12.05, inclusive, and states that full information on the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder. After this sale, Banerjee's direct beneficial ownership stood at 142,047 shares of common stock.

The filing also reflects that Banerjee holds 74,265 employee stock options with an exercise price of $1.92 and an expiration date of April 7, 2035. Both the option exercise and the share sale are reported as having been made pursuant to a Rule 10b5-1 plan that Banerjee adopted on May 14, 2026. The form was signed by Andrew Cronauer as Attorney-in-Fact and filed on August 31, 2026.

What Was Disclosed

The filing disclosed a stock option exercise of 5,306 shares and a subsequent sale of 8,222 common shares by Artiva Biotherapeutics' Chief Medical Officer on August 27, 2026, both conducted under a pre-established Rule 10b5-1 trading plan.